MK169 is an IL-1beta inhibitor. MK169 reduces LPS (HY-D1056)-induced IL-1beta release in human aortic smooth muscle cells. MK169 is applicable to the research of cardiovascular inflammatory diseases such as atherosclerosis[1].
Molecular Weight:
412.53
Formula:
C16H24N6O3S2
Target:
Interleukin Related
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
